These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 29407054)

  • 1. Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients.
    Lovre D; Shah S; Sihota A; Fonseca VA
    Endocrinol Metab Clin North Am; 2018 Mar; 47(1):237-257. PubMed ID: 29407054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin use in patients with diabetes and kidney disease: the Japanese experience.
    Koya D; Campese VM
    J Atheroscler Thromb; 2013; 20(5):407-24. PubMed ID: 23518468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is lipid management effective for all stages of CKD?
    Ku E; Campese V
    Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.
    Athyros VG; Tziomalos K; Karagiannis A
    Expert Rev Cardiovasc Ther; 2015; 13(9):1059-66. PubMed ID: 26206619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National survey: Evaluation of cardiovascular risk factors in Thai patients with type 2 diabetes and chronic kidney disease after the development of cardiovascular disease.
    Changsirikulchai S; Sangthawan P; Janma J; Sripaiboonkij N; Rattanamongkolgul S; Thinkhamrop B
    Nephrology (Carlton); 2018 Jan; 23(1):53-59. PubMed ID: 27608176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance of treatment for dyslipidemia in CKD].
    Ikemori A; Kimura K
    Nihon Jinzo Gakkai Shi; 2013; 55(7):1287-94. PubMed ID: 24288965
    [No Abstract]   [Full Text] [Related]  

  • 7. Diabetes-Related Dyslipidemia and Cardiovascular Events.
    Fonseca VA; Lovre D
    Am J Med Sci; 2017 Aug; 354(2):103-104. PubMed ID: 28864365
    [No Abstract]   [Full Text] [Related]  

  • 8. Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease?
    Zuzda K; Grycuk W; Małyszko J; Małyszko J
    Expert Opin Ther Targets; 2022 Nov; 26(11):995-1009. PubMed ID: 36548906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
    Fruchart JC; Hermans MP; Fruchart-Najib J
    Curr Atheroscler Rep; 2020 Jul; 22(8):43. PubMed ID: 32671476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyslipidemia in Patients with Kidney Disease.
    Thobani A; Jacobson TA
    Cardiol Clin; 2021 Aug; 39(3):353-363. PubMed ID: 34247749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incremental risk of cardiovascular disease and/or chronic kidney disease for future ASCVD and mortality in patients with type 2 diabetes mellitus: ACCORD trial.
    Branch M; German C; Bertoni A; Yeboah J
    J Diabetes Complications; 2019 Jul; 33(7):468-472. PubMed ID: 31088728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diabetes mellitus related common medical disorders: recent progress in diagnosis and treatment topics: I. Pathophysiology, diagnosis and treatment: 9. Dyslipidemia].
    Arai H
    Nihon Naika Gakkai Zasshi; 2013 Apr; 102(4):890-4. PubMed ID: 23772503
    [No Abstract]   [Full Text] [Related]  

  • 13. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists.
    Serowik TC; Pantalone KM
    J Osteopath Med; 2024 Mar; 124(3):127-135. PubMed ID: 37921061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-modifying therapy in chronic kidney disease: Pathophysiological and clinical considerations.
    Heine GH; Eller K; Stadler JT; Rogacev KS; Marsche G
    Pharmacol Ther; 2020 Mar; 207():107459. PubMed ID: 31863818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyslipidemia in chronic kidney disease.
    Kowalski A; Krikorian A; Lerma EV
    Dis Mon; 2015 Sep; 61(9):396-402. PubMed ID: 26315102
    [No Abstract]   [Full Text] [Related]  

  • 17. Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients.
    Chen SC; Tseng CH
    Rev Diabet Stud; 2013; 10(2-3):88-100. PubMed ID: 24380085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease in chronic kidney disease: risk factors, pathogenesis, and prevention.
    Ardhanari S; Alpert MA; Aggarwal K
    Adv Perit Dial; 2014; 30():40-53. PubMed ID: 25338421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic kidney disease and dyslipidaemia].
    Pascual V; Serrano A; Pedro-Botet J; Ascaso J; Barrios V; Millán J; Pintó X; Cases A
    Clin Investig Arterioscler; 2017; 29(1):22-35. PubMed ID: 27863896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.
    Lamprea-Montealegre JA; Staplin N; Herrington WG; Haynes R; Emberson J; Baigent C; de Boer IH;
    Clin J Am Soc Nephrol; 2020 Jan; 15(1):47-60. PubMed ID: 31831577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.